Роль омега-3 полиненасыщенных жирных кислот в лечении прогрессирующих заболеваний почек


Цитировать

Полный текст

Аннотация

В обзоре представлено значение омега-3 полиненасыщенных жирных кислот в лечении хронических прогрессирующих заболеваний почек у детей.

Об авторах

Е В Кулина

ФГБУ «Московский НИИ Педиатрии и детской хирургии» Минздравсоцразвития России

ФГБУ «Московский НИИ Педиатрии и детской хирургии» Минздравсоцразвития России

Список литературы

  1. Kromann N, Green A. Epidemiological studies in the Upernavic district Grenland: incidence of some chronic disease 1950-1974. Acta Med Scand. 1980; 208; 401-4066.
  2. Dyeberg J, Band HO, Hjorne N. Fatty acid composition of the plasma lipids in Grenland Eskumos. Am Clin-Nutr. 1975; 28: 958-966.
  3. León H., Shibata M.C., Sivakumaran S. et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ . 2008; 337: 2931.
  4. Steiber A., Omega-3 fatty acids may benefit dialysis patients Clin Hypertens 2010; 32: 137-144.
  5. Fekete K., Marosvolgyli T., Jakobik V., Decs T.i Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: a systematic review1-5 Am J Clin Nutr 2009; 89: 2070S-2084S.
  6. Reynolds J.L., Wetze D.L.l, O'Hara T.M. Human health implications of omega-3 and omega-6 fatty acids in blubber of the Bowhead Whale (Balaena mysticetus) J. Arctic 2006; 59 (2): 155-164
  7. Riediger N.D., Othman R.A., Suh M., Moghadasian M.H. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet Assoc. 2009; 109(4): 668-679.
  8. Сalder P. C. Fatty acids metabolism and eicosanoid synthesis. Clinical. Nutrition. 2001; 20: 1-5.
  9. Левачев М. М. Значение жира в питании здорового и больного человека: В: Тутельян В.А., Самсонов М.А. (ред.) Справочник по диетологии. М.: Медицина. 2002. С. 25-32.
  10. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med. 1988; 318(9): 549-557.
  11. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc. Health Risk Manag. 2006; 2(3): 251-262.
  12. Kromhout D. Diet and cardiovascular diseases. J. Nutr. Health. Aging. 2001; 5(3): 144-149.
  13. Djousse L., Folsom A. R., Province M. A., Hunt S. C., Ellison R. C. National Heart, Lung, and Blood Institute Family Heart Study. Dietary linolenic acid and carotid atherosclerosis. Am. J. Clin. Nutr. 2003; 77 (4): 819-825.
  14. Rosenberg TH. Fish food to calm the heart. N Engl J Med. 2002; 346: 1102-1103.
  15. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology Science. 2001; 294: 1871-1875.
  16. Brink C., Dahlen S.E., Drazen J.et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors Pharmacol Rev. 2003; 55: 195-227.
  17. Bos C.L., Richel D.J., Ritsema T. et al. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004; 36.: 1187-1205.
  18. Reiffel J.A., McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am. J. Cardiol. 2006; 98: 50-60.
  19. Северин. Е.С.Биохимия. М. Гэотар-Мед.2004
  20. Fischer S., Weber P.C. Thromboxane (TX)A3 and prostaglandin (PG)I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry. Biomed Mass Spectrom. 1985; 12: 470-476.
  21. Martyn B.J. Prostaglandins, leukotrienes, and lipoxins: biochemistry, mechanism of action, and clinical applications Plenum Press, New York.1985
  22. Serhan C.N. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care. 2005; 8: 115-121.
  23. Bazan N.G. The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol. 2006; 26: 4-6
  24. Bazan N.G. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care. 2007; 10: 136-141.
  25. Levant B., Ozias M.K., Jones K.A., Carlson S.E. Differential effects of modulation of docosahexaenoic acid content during development in specific regions of rat brain. Lipids. 2006; 41: 407-414.
  26. Ortmann O., Catt K.J., Schulz K.D., Emons G. Modulatory action of progesterone and progesterone antagonists on hypothalamic-pituitary function . Hum Reprod. 1994; 9(Suppl 1): 53-62.
  27. Kotani S., Sakaguchi E., Warashina S.et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006; 56: 159-164.
  28. Catalan J., Moriguchi T., Slotnick B. et al. Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci. 2002; 116: 1022-1031.
  29. Akbar M., Calderon F., Wen Z., Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA. 2005; 102: 10858-10863.
  30. Gonzalez-Periz A., Planaguma A., Gronert K. et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 2006; 20: 2537-2539.
  31. German O.L., Insua M.F., Gentili C., Rotstein N.P., Politi L.E. Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem. 2006; 98: 1507-1520.
  32. Lukiw W.J., Bazan N.G. Docosahexaenoic acid and the aging brain. J Nutr. 2008; 138: 2510-2514.
  33. Khalfoun B., Thibault F., Watier H., Bardos P., Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol. 1997; 400: 589-597.
  34. Li Q., Ma J., Tan L., Wang C. et al. Effect of docosahexaenoic acid on interleukin-2 receptor signaling pathway in lipid rafts. Sci China C Life Sci. 2006; 49: 63-72.
  35. Pan H.C., Kao T.K., Ou Y.C. et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J. Nutr. Biochem. 2009; 20:715-725.
  36. Hao CM, Breyer MD. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 2007; 71: 1105-1115
  37. Dwyer JH, Allayee H, Dwyer KM et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350: 29-37
  38. Clark WF, Parbtani A, Philbrick DJ, Holub BJ, Huff MW. Chronic effects of omega-3 fatty acids (fish oil) in a rat 5/6 renal ablation model. J Am Soc Nephrol 1991; 1: 1343-1353
  39. Hagiwara S, Makita Y, Gu L et al. Eicosapentaenoicacid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice:involvement of MCP-1 suppression and decreased ERK1/2 and p38phosphorylation. Nephrol Dial Transplant 2006; 21: 605-615
  40. Sabry A., El-Dahshan K., El-Hussieni A. Prevention of chronic cyclosporine nephrotoxicity in Sprague-Dawley rats: role of colchicine and omega-3-fatty acids. Int Urol Nephrol. 2007; 39: 271-273.
  41. Garman J.H., Mulroney S., Manigrasso M. et al: Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol. 2009; 296: F306-F316.
  42. An W.S. , Kim H.J., Cho K.H., Vaziri1 N.D. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol 2009; 297: F895-F903
  43. De Caterina R., Capriori R., Giannessi D. n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney. Int. 1993; 44: 843-850.
  44. Henderson J. Dietary considerations in chronic kidney disease. Nat. Med. J. 2010; 2(9): 12
  45. Svensson E.B., Jшrgensen K.J., Christensen J.P. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol. Dial. Transplant. 2008; 23 (9): 2918-2924.
  46. Вознесенская Т. C., Кутафина Е. К. и др. Влияние омега-3полиненасыщенных жирных кислот на показатели липидного обмена у детей с нефротическим синдромом. Вопросы детской диетологии. 2003; 1 (2): 90-93.
  47. Kwan, BC, Kronenberg, F, Beddhu, S, Cheung, AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007; 18: 1246.
  48. Weiner, DE, Sarnak, MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004; 19: 1045.
  49. Keith DS, Nichols GA, Gullion CM, et al: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organiza- tion. Arch Intern Med.2004; 164: 659-663
  50. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int.1993; 44: 638-642

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах